Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-HELLS, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SMARCA6 also known as SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 6 is a protein with a molecular weight of approximately 170 kDa. It functions as an ATPase and is an important component of chromatin remodeling complexes. SMARCA6 plays a role in modifying chromatin structure through ATP hydrolysis which influences gene expression. This protein is expressed in various tissues and its expression can be detected across different cell types including those involved in blood functions.
Biological function summary
SMARCA6 influences gene expression by modifying the chromatin structure which allows transcription factors to access DNA. It is a part of the SWI/SNF chromatin remodeling complex critical for regulating a wide range of genes involved in development and cell cycle. Through the remodeling of chromatin SMARCA6 controls access to specific genomic regions and modulates transcriptional activation or repression therefore influencing cellular differentiation and proliferation.
Pathways
SMARCA6 participates in pathways involved in chromatin organization and gene regulation. It engages in the Wnt signaling pathway interacting with proteins such as BAF155 and BAF170 to modulate transcriptional outcomes. SMARCA6's activity in these pathways is essential for cellular processes impacting how cells respond to growth signals and maintain homeostasis.
Aberrations in SMARCA6 function or expression can lead to complications such as cancer and neurodevelopmental disorders. It has been linked to leukemia where chromatin remodeling anomalies disrupt normal gene expression patterns. In such contexts SMARCA6 interacts with proteins like BAF57 affecting the regulation of oncogenes and tumor suppressors. Altered SMARCA6 activity in these diseases highlights its role in maintaining genomic stability and proper cell function.
